Shanna Babalonis, PhD
The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can alter the drive/desire to take opioids.
Inclusion Criteria: * Participants with moderate to severe opioid use disorder who experience opioid withdrawal * No allergies or adverse reactions to cannabis or opioids * Willing to stay inpatient at the UK Hospital research center for approx. 6 weeks Exclusion Criteria: * Individuals seeking treatment for opioid use disorder
Cannabis is administered three times daily during the active cannabis treatment period.
Matched placebo cannabis is administered three times daily during the placebo treatment period.
Intranasal opioid agonists are administered during sample and self-administration sessions
Oral opioid agonist maintenance doses are administered four times daily throughout study participation.
Arctuva estimate
Verify or correct the compensation shown for this listing.